We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Guidelines Issued on Appropriate Use of Platelet Transfusion

By LabMedica International staff writers
Posted on 23 Nov 2014
Platelet transfusions are administered to prevent or treat bleeding in patients with quantitative or qualitative platelet disorders and new guidelines have been issued that specify clinical situations in which platelet transfusion is recommended in adult patients.

The developed guidelines address several common clinical situations and attempt to identify a platelet count threshold below which platelet transfusion may improve hemostasis and above which platelet transfusion is unlikely to benefit the patient.

Led by hematologists at the Brigham and Women's Hospital (Boston MA, USA) a team of scientists performed a systematic review of randomized, clinical trials and observational studies that reported clinical outcomes on patients receiving prophylactic or therapeutic platelet transfusions. More...
A literature search from 1900 to September 2014 with no language restrictions was done. Examined outcomes included all-cause mortality, bleeding-related mortality, bleeding, and number of platelet units transfused. An expert panel reviewed the data and developed recommendations using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework.

The AABB (formerly, the American Association of Blood Banks, Bethesda, MD, USA) recommends prophylactic platelet transfusion to reduce the risk for spontaneous bleeding in hospitalized adult patients with therapy-induced hypoproliferative thrombocytopenia and a platelet count of 10 × 109 cells/L. There is weaker evidence to suggest that prophylactic platelet transfusion should be administered in patients having elective central venous catheter placement with a platelet count of less than 20 × 109 cells/L or patients having elective diagnostic lumbar puncture or major elective non-neuraxial surgery with a platelet count less than 50 × 109 cells/L.

The team recommended against routine prophylactic platelet transfusion in patients who are non-thrombocytopenic and have cardiac surgery with cardiopulmonary bypass but suggests, without recommending, that those with perioperative bleeding and thrombocytopenia or platelet dysfunction may benefit from transfusion. They concluded that the ideal approach to platelet transfusion would be to administer sufficient platelets to optimize patient outcomes while avoiding unnecessary transfusions with their attendant risks and costs. The recommendations in their guideline reflect the AABB's current thinking on how platelet transfusions should be used in various clinical settings. The study was published on November 11, 2014, in the journal Annals of Internal Medicine.

Related Links:

Brigham and Women's Hospital
AABB 



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Aspiration System
VACUSAFE
Thyroid Test
Anti-Thyroid EIA Test
Automated Urinalysis Solution
UN-9000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New findings demonstrate that anti-Müllerian hormone (AMH) may help identify which breast cancer patients are most likely to benefit from chemotherapy plus endocrine therapy (Image Credit: Shutterstock)

AMH Test Helps Predict Adjuvant Chemotherapy Benefit in Premenopausal Breast Cancer

Hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer can present a difficult treatment decision in premenopausal patients with low recurrence scores.... Read more

Molecular Diagnostics

view channel
Image Credit: iStock

Sequencing-Based Newborn Screening Identifies Pediatric Cancer Risk at Birth

Newborn screening in the United States relies on heel-stick blood spots to identify rare, treatable disorders through biochemical testing, but these programs generally do not assess inherited cancer risk... Read more

Microbiology

view channel
Image: The QIAstat-Dx BCID GPF Plus AMR Panel is the first QIAstat-Dx panel for bloodstream infections to receive FDA clearance (Photo courtesy of Qiagen)

FDA Clears One-Hour Panel for Bloodstream Infection and AMR Detection

Bloodstream infections can rapidly progress to sepsis, a life-threatening condition affecting an estimated 1.7 million adults in the U.S. each year. Rapid identification of pathogens and antimicrobial... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.